RP3 PrEP Choice

RP3 PrEP 选择

基本信息

  • 批准号:
    10595903
  • 负责人:
  • 金额:
    $ 6.14万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-01-25 至 2029-11-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Young persons, aged 13-24 years, accounted for 21% of new infections in the United States in 2018, and 81% of these occurred in young gay, bisexual, and other men who have sex with men (YGBMSM). Currently, there are 4 different regimens of pre-exposure prophylaxis (PrEP) available for YGBMSM: 1) daily tenofovir disoproxil fumarate co-formulated with emtricitabine (TDF/FTC), 2) daily tenofovir alafenamide co-formulated with emtricitabine (TAF/FTC), 3) peri-coital TDF/FTC (“2-1-1 PrEP”), and 4) injectable long-acting cabotegravir. PrEP Choice is a package of three mobile health tools designed to increase the uptake and adherence to PrEP for YGBMSM, aged 13-24 years, to be tested in multiple sites in the United States. PrEP Choice consists of 1) MyPrEP, a website to help YGBMSM choose the type of PrEP that works best for them; 2) PrEPmate, a two- way SMS texting tool to check in with YGBMSM on a weekly basis and troubleshoot any problems with PrEP that arise; and 3) PrEPsmart, an app that reminds PrEP users taking PrEP pills when their next pill should be taken. These tools have been developed and tested individually; this is the first study to test the package of these tools to see if they increase the proportion of YGBMSM who take PrEP, and their adherence to PrEP once they start. The study begins by ensuring that PrEP Choice is relevant for both Spanish- and English- speaking YGBMSM across the country, through the use of focus groups, followed by a technical pilot in 20 YGBMSM, to work out any bugs in the system and to help determine how best to apply PrEP Choice in this population. Then, 200 YGBMSM not currently on PrEP will be recruited into a trial in which 100 are randomly chosen to get PrEP Choice, and the other 100 are randomly chosen to get a brochure describing the different types of PrEP available. After 9 months of follow-up, PrEP starts and use over time will be compared between the two groups. Then, the 100 participants initially given the brochure only will get access to the PrEP Choice package, and both groups will be followed for another 9 months to study their use of PrEP over time. PrEP use will be measured by testing for tenofovir diphosphate (TFV-DP) levels in dried blood spots (for the 3 types of PrEP that use pills) or the number of PrEP injections they get (for injectable long acting cabotegravir.) The primary outcome is PrEP use at 9 months into the study, and this study will enroll enough participants to be able to tell whether there is at least a 20% increase in the proportion of YGBMSM who use any PrEP in the PrEP Choice group compared with the brochure group, and a 22.5% increase in PrEP adherence (as measured by TFV-DP levels or administration of long-acting cabotegravir) in the PrEP Choice group compared with the brochure group. The cost and cost-effectiveness of the PrEP Choice package will also be assessed for YGBMSM. The trial will be conducted through the Adolescent Trials Network for HIV/AIDS Interventions (ATN), making use of their biostatistical and modeling resources, geographic and site diversity, and multidisciplinary expertise, including young advisors from the target population.
项目摘要 2018年,13-24岁的年轻人占美国新感染人数的21%, 这些发生在年轻的同性恋,双性恋和其他与男性发生性关系的男性(YGBMSM)。目前 有4种不同的暴露前预防(PrEP)方案可用于YGBMSM:1)每日替诺福韦 与恩曲他滨(TDF/FTC)共同配制的富马酸二异丙酯,2)每日共同配制的替诺福韦艾拉酚胺 与恩曲他滨(TAF/FTC),3)性交周TDF/FTC(“2-1-1 PrEP”),和4)可注射的长效卡替拉韦。 PrEP Choice是一套由三种移动的健康工具组成的软件包,旨在提高PrEP的使用率和依从性 对于13-24岁的YGBMSM,将在美国的多个地点进行测试。PrEP选择包括1) MyPrEP,一个帮助YGBMSM选择最适合他们的PrEP类型的网站; 2)PrEPmate,一个两个- 通过短信工具每周与YGBMSM联系并解决PrEP的任何问题 出现;和3)PrEPsmart,一个应用程序,提醒服用PrEP药丸的PrEP用户,当他们的下一个药丸应该 满员你这些工具已经单独开发和测试;这是第一项测试 这些工具,看看他们是否增加了YGBMSM谁采取PrEP的比例,以及他们坚持PrEP 一旦他们开始。该研究首先确保PrEP选择与西班牙语和英语相关, 通过使用焦点小组,在全国范围内讲YGBMSM,然后在20个国家进行技术试点, YGBMSM,以解决系统中的任何错误,并帮助确定如何最好地应用PrEP的选择, 人口然后,200名目前未接受PrEP的YGBMSM将被招募到一项试验中, 选择获得PrEP选择,其他100人随机选择获得描述不同 可用的PrEP类型。在9个月的随访后,将比较PrEP的开始和随时间的使用, 这两个群体。然后,最初仅获得小册子的100名参与者将获得PrEP Choice 包装,两组将被随访另外9个月,以研究他们随着时间的推移使用PrEP。PrEP使用 将通过测试干血斑中的替诺福韦二磷酸(TFV-DP)水平来测量(对于3种类型的 使用药丸的PrEP)或他们获得的PrEP注射次数(对于可注射的长效cabotegravir)。的 主要结局是研究9个月时的PrEP使用,本研究将招募足够的参与者, 能够判断是否有至少20%的比例增加YGBMSM谁使用任何PrEP在 PrEP选择组与手册组相比,PrEP依从性增加了22.5%(作为 通过TFV-DP水平或长效cabotegravir给药测量), 宣传册小组的人PrEP选择包的成本和成本效益也将进行评估, YGBMSM。该试验将通过艾滋病毒/艾滋病干预青少年试验网络(ATN)进行, 利用其生物统计和建模资源、地理和地点多样性以及多学科 专业知识,包括来自目标人群的青年顾问。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lisa B Hightow-Weidman其他文献

Studying the Digital Intervention Engagement–Mediated Relationship Between Intrapersonal Measures and Pre-Exposure Prophylaxis Adherence in Sexual and Gender Minority Youth: Secondary Analysis of a Randomized Controlled Trial
研究数字干预参与度——性少数青年中人际测量与暴露前预防依从性之间的中介关系:一项随机对照试验的二次分析
  • DOI:
    10.2196/57619
  • 发表时间:
    2025-01-01
  • 期刊:
  • 影响因子:
    6.000
  • 作者:
    Michael P Williams;Justin Manjourides;Louisa H Smith;Crissi B Rainer;Lisa B Hightow-Weidman;Danielle F Haley
  • 通讯作者:
    Danielle F Haley

Lisa B Hightow-Weidman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lisa B Hightow-Weidman', 18)}}的其他基金

Scientific Leadership Group Core
科学领导小组核心
  • 批准号:
    10595900
  • 财政年份:
    2023
  • 资助金额:
    $ 6.14万
  • 项目类别:
RP4 LEAP
RP4飞跃
  • 批准号:
    10595904
  • 财政年份:
    2023
  • 资助金额:
    $ 6.14万
  • 项目类别:
RP5 MPT Study
RP5 MPT 研究
  • 批准号:
    10595905
  • 财政年份:
    2023
  • 资助金额:
    $ 6.14万
  • 项目类别:
Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Scientific Leadership Center
艾滋病毒/艾滋病干预青少年医学试验网络 (ATN) 科学领导中心
  • 批准号:
    10595899
  • 财政年份:
    2023
  • 资助金额:
    $ 6.14万
  • 项目类别:
RP1 Screen 2 Prevent
RP1 屏蔽 2 预防
  • 批准号:
    10595901
  • 财政年份:
    2023
  • 资助金额:
    $ 6.14万
  • 项目类别:
RP7 Impact
RP7 影响
  • 批准号:
    10595907
  • 财政年份:
    2023
  • 资助金额:
    $ 6.14万
  • 项目类别:
Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN)Scientific Leadership Center; ADMIN SUPPLEMENT
艾滋病毒/艾滋病干预青少年医学试验网络 (ATN) 科学领导中心;
  • 批准号:
    10855435
  • 财政年份:
    2023
  • 资助金额:
    $ 6.14万
  • 项目类别:
PrEP Choice: Increasing the Use of HIV Pre-exposure Prophylaxis in an Era of Choices
PrEP 选择:在选择时代增加 HIV 暴露前预防的使用
  • 批准号:
    10775220
  • 财政年份:
    2022
  • 资助金额:
    $ 6.14万
  • 项目类别:
PrEP Choice: Increasing the Use of HIV Pre-exposure Prophylaxis in an Era of Choices
PrEP 选择:在选择时代增加 HIV 暴露前预防的使用
  • 批准号:
    10804710
  • 财政年份:
    2022
  • 资助金额:
    $ 6.14万
  • 项目类别:
The UNC/Emory Center for Innovative Technology (iTech) across the prevention and care continuum
北卡罗来纳大学/埃默里大学创新技术中心 (iTech) 涵盖预防和护理连续体
  • 批准号:
    10399185
  • 财政年份:
    2021
  • 资助金额:
    $ 6.14万
  • 项目类别:

相似海外基金

Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 6.14万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
  • 批准号:
    10100360
  • 财政年份:
    2024
  • 资助金额:
    $ 6.14万
  • 项目类别:
    Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
  • 批准号:
    24K04974
  • 财政年份:
    2024
  • 资助金额:
    $ 6.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
  • 批准号:
    23K01686
  • 财政年份:
    2023
  • 资助金额:
    $ 6.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
  • 批准号:
    23K01692
  • 财政年份:
    2023
  • 资助金额:
    $ 6.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
  • 批准号:
    23K01695
  • 财政年份:
    2023
  • 资助金额:
    $ 6.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
  • 批准号:
    23K01713
  • 财政年份:
    2023
  • 资助金额:
    $ 6.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
  • 批准号:
    2312319
  • 财政年份:
    2023
  • 资助金额:
    $ 6.14万
  • 项目类别:
    Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
  • 批准号:
    23K01715
  • 财政年份:
    2023
  • 资助金额:
    $ 6.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
  • 批准号:
    10585388
  • 财政年份:
    2023
  • 资助金额:
    $ 6.14万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了